¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Current topics in cellular regulation."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • alternating current
    ±³·ù
  • ampullopetal endolymph current
    ÆØ´ëºÎÇ⼺¸²ÇÁ·ù
  • capacitative current
    ÃàÀü±âÀü·ù
  • co-current flow
    ¹Ù¸¥È帧, Á¤È帧
  • current
    Àü·ù
  • dark current
    ¾ÏÀü·ù
  • direct current
    Á÷·ù
  • eddy current
    ¼Ò¿ëµ¹ÀÌÀü·ù
  • effective current
    À¯È¿Àü·ù
  • high frequency current
    °íÁÖÆÄÀü·ù
  • inward current
    ³»ÇâÀü·ù
  • ionization current
    ÀÌ¿ÂÈ­Àü·ù
  • insensible air current
    ºÒ°¨±â·ù
  • local current
    ±¹¼ÒÀü·ù
  • minimal current gradient
    ÃÖ¼ÒÀü·ù±â¿ï±â, ÃÖ¼ÒÀü·ù°æ»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cellular sensitivity
    ¼¼Æ÷¹Î°¨µµ
  • cellular type
    ¼¼Æ÷Çü
  • mixed cellular cast
    È¥ÇÕ¼¼Æ÷¿øÁÖ
  • impaired cellular immunity
    ¼¼Æ÷¸é¿ªºÎÀü
  • action current
    Ȱµ¿Àü·ù
  • air current
    ±â·ù
  • alternating current
    ±³·ù
  • ampullopetal endolymph current
    ÆØ´ëºÎÇ⼺¸²ÇÁ·ù
  • ascending current
    »óÇàÀü·ù
  • axial current
    ÃàÈ帧, Ãà·ù
  • current
    Àü·ù
  • capacitative current
    ÃàÀü±âÀü·ù
  • co-current flow
    ¹Ù¸¥È帧, Á¤È帧
  • current disinfection
    ´ç½Ã¼Òµ¶
  • current mark
    Àü·ù¹Ý, Àü·ùÀÚ±¹
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cellular connective tissue
    ¼¼Æ÷¼º°áÇÕÁ¶Á÷
  • cellular deficiency (acallosal cerebrum)
    ¼¼Æ÷°áÇÌ (³úµéº¸°á¿©³ú)
  • cellular detection
    ¼¼Æ÷°ËÃâ
  • cellular granule
    ¼¼Æ÷°ú¸³
  • cellular hypersensitivity
    ¼¼Æ÷¼º °ú¹Î¹ÝÀÀ
  • cellular hypersensitivity
    ¼¼Æ÷¼º°ú¹Î¹ÝÀÀ
  • cellular immunity
    ¼¼Æ÷¸é¿ª
  • cellular immunity
    ¼¼Æ÷(¼º)¸é¿ª(¡­Øóæ¹).
  • cellular infiltration
    ¼¼Æ÷ħÀ±(¡­öÙëÈ).
  • cellular interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • cellular invagination
    ¼¼Æ÷ÇÔÀÔ
  • cellular islands
    ¼¼Æ÷¼¶
  • cellular layer
    ¼¼Æ÷ÆÇ
  • cellular membrane
    ¼¼Æ÷¼º¸·
  • cellular nevus
    ¼¼Æ÷¼º¸ð¹Ý
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HCCa Hepato-Cellular Cacinoma
ICAMs Inter-Cellular Adhesion Molecules
ICF Intra-Cellular Fluid; ¼¼Æ÷³»¾×
CAI cellular adaptive immunotherapy; complete androgen insensitivity; computer-assisted instruction
CAP camptodactyly-arthropathy-pericarditis [syndrome]; Canada Assistance Plan; capsule; captopril; catab...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CAM Cellular adhesion molecules
CFA Cellular fatty acid
cFN Cellular fibronectin
c-onc cellular oncogene
CRALBP Cellular retinaldehyde binding protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute cellular rejecion
    ±Þ¼º ¼¼Æ÷¼º °ÅºÎ
    ÀϹÝÀûÀ¸·Î ÀÌ½Ä ÈÄ ¼ö °³¿ù ³»¿¡ ¹ß»ýÇϸç Ç÷û Å©·¹¾ÆÆ¼´ÑÄ¡°¡ »ó½ÂÇÏ°í ±Þ¼º ½ÅºÎÀüÀÇ ÀÓ»óÁõ»óÀ» µ¿¹ÝÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â °£Áú³» ´ÜÇÙ¼¼Æ÷ ħÀ±ÀÌ ¸Å¿ì °­ÇÏ°Ô ³ªÅ¸³ª¸ç, ºÎÁ¾ ¹× °æµµÀÇ °£Áú³» ÃâÇ÷À» º¸À̴µ¥ »ç¶÷ÀÇ °æ¿ì ´ÜÇÙ¼¼Æ÷´Â ÁÖ·Î Áß°£ Å©±â¿Í ÀÛÀº ¸²ÇÁ±¸·Î ±¸¼ºµÇ¾î ÀÖ°í dzºÎÇÑ È£¿°±â¼º ¼¼Æ÷Áú°ú ¼öÆ÷¼º ÇÙÀ» °¡Áø ¼Ò¼öÀÇ ÇüÁú¼¼Æ÷ ħÀ±µµ º¼ ¼ö ÀÖ´Ù.
  • cellular
    ¼¼Æ÷¼º, ¼¼Æ÷ÀÇ
  • cellular adhesiveness
    ¼¼Æ÷ ºÎÂø¼º
    ¼¼Æ÷°£¿¡ ¹°¸®ÀûÀÎ Àη ¶Ç´Â Á¢Ã˹°Ã¼ÀÇ Ç¥¸é°£¿¡ Á¸ÀçÇÏ´Â ºÐÀÚÀη¿¡ ÀÇÇÑ ºÎÂø¼º.
  • cellular antibody
    ¼¼Æ÷ Ç×ü
    ƯÀÌÀûÀÎ ¾Æ¹Ì³ë»ê ¹è¿­À» °¡Áø ¼¼Æ÷¼º ¸é¿ª ±Û·ÎºÒ¸° ºÐÀÚ.
  • cellular axis
    ¼¼Æ÷ Ãà
    ¼¼Æ÷¿¡¼­ ¾î¶² ±¸Á¶¹°À̳ª ȸÀüü°¡ ÁÖÀ§¸¦ µ¹°í ÀÖ´Â Á÷¼±.
  • cellular blue nevus
    ¼¼Æ÷¼º û»ö ¸ð¹Ý
    û»ö ¸ð¹ÝÀÇ Æ¯ÀÌÇÑ º¯ÇüÀ¸·Î¼­ ÀÓ»óÀû ¹× Á¶Á÷ÇÐÀûÀ¸·Î ¾Ç¼º Èæ»öÁ¾À¸·Î ¿ÀÀεDZ⠽±´Ù. À̰ÍÀº µÐºÎ¿Í õ¹Ì°ñ ºÎÀ§¿¡ È£¹ßÇϸç Ä¿´Ù¶õ û»ö ¶Ç´Â Èæ»öÀÇ ´Ü´ÜÇÑ °áÀý·Î ³ªÅ¸³­´Ù.
  • cellular cementum
    ¼¼Æ÷¼º ¹é¾ÇÁú
    Ä¡¾ÆÀÇ Ä¡±Ù¸éÀ» µ¤°í ÀÖ´Â ¼®È¸È­µÈ ¹°ÁúÀÇ ºÎºÐ. °ñ°ú ºñ½ÁÇÏ¸ç ¹é¾Ç ¼¼Æ÷°¡ ¼Ò¿Í³»¿¡¼­ ¹¯Çô ÀÖ´Ù. ¶ÇÇÑ, ¹é¾ÇÁúÀÇ ¼¼°üÀ» µû¶ó ¿øÇüÁú µ¹±â°¡ »¸¾î ÀÖ°í ÀÌ´Â ÀÎÁ¢ÇÑ ¼Ò¿ÍÀÇ ¼¼°ü°ú ¹®ÇÕÇÑ´Ù. ¼Ò¿Í´Â ÃþÆÇÇüÀ¸·Î Á¤·ÄÇÏ¿© ¼®È¸Áú¿¡ »êÀçÇØ ÀÖ´Ù. ¼¼Æ÷¼º ¹é¾ÇÁúÀº ÁÖ·Î Ä¡±ÙÀÇ Ä¡±Ù´Ü ºÎºÐ¿¡ ±¹¼ÒÈ­µÇ¾î Àִµ¥ ¹«¼¼Æ÷¼º ¹é¾ÇÁú À§¿¡ Ä§ÂøµÉ ¼öµµ ÀÖ°í, ¹é¾ÇÁú Èí¼ö ºÎÀ§¿¡¼­ Ä¡À¯ ÀÛ¿ëÀ» ÇÏÁö ¸øÇÒ ¼öµµ ÀÖ´Ù.
  • cellular connective tissue
    ¼¼Æ÷¼º °áÇÕ Á¶Á÷
    ¼¼Æ÷·Î »çÀ̰¡ ¿¬°áµÇ¾î ÀÖ´Â Á¶Á÷.
  • cellular deficiency
    ¼¼Æ÷ °áÇÌ
    ¼¼Æ÷°¡ À¯ÀüÀû ȤÀº ÀÚ°¡¸é¿ªÀû ¿äÀÎÀ¸·Î ÀÎÇØ¼­ °áÇÌµÈ °Í.
  • cellular detection
    ¼¼Æ÷ °ËÃâ
    ¼¼Æ÷ÀÇ Á¸À縦 °ËÃâÇÏ´Â °Í.
  • cellular hypersensitivity
    ¼¼Æ÷¼º °ú¹Î¹ÝÀÀ
    ¼¼Æ÷¿¡ ´ëÇÏ¿© °úÀ×¹ÝÀÀÀ» ³ªÅ¸³»´Â ¹æÇâÀ¸·Î ¹ÝÀÀ¼ºÀÌ º¯È­ÇÑ »óÅÂ.
  • cellular infiltration
    ¼¼Æ÷ ħÀ±
    ¼¼Æ÷°¡ ħÀ±¿¡ ÀÇÇÏ¿© Ä§ÂøµÈ °Í.
  • cellular invagination
    ¼¼Æ÷ ÇÔÀÔ
    ¼¼Æ÷ÀÇ ¾î¶² ºÎºÐÀÌ ´Ù¸¥ ºÎºÐ³»¿¡ ÇÔÀÔÇÏ´Â °Í.
  • cellular layer
    ¼¼Æ÷ Ãþ
    ¼¼Æ÷°¡ °ÅÀÇ ÀÏÁ¤ÇÑ µÎ²²ÀÇ, ȬÀ̺Ҹð¾çÀÇ Á¶Á÷ ±¸Á¶¸¦ °¡Áö´Â °Í.
  • cellular membrane
    ¼¼Æ÷¼º ¸·
    ¼¼Æ÷ÀÇ Ç¥¸éÀ» µ¤°Å³ª °øµ¿ÀÇ ³»¸éÀ» µ¤´Â, ¶Ç´Â °ø°£À̳ª ±â°üÀ» ³ª´©´Â ¾ãÀº ÃþÀÇ Á¶Á÷.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
cellular polyp A polyp that consists of benign neoplastic tissue derived from glandular epithelium.
Synonym: cellular polyp, polypoid adenoma.
(05 Mar 2000)
cellular respiration <biochemistry> The conversion within the cell of nutrients (such as sugar molecules) into chemical energy in the form of ATP, by reacting the food with oxygen (O2) until the food has completely been degraded into carbon dioxide and H2O.
(09 Oct 1997)
cellular retinoic acid binding protein <protein> A cytoplasmic fatty acid binding protein that acts as an initial receptor for the putative morphogen, retinoic acid.
(18 Nov 1997)
cellular slime mould See: Acrasidae.
(18 Nov 1997)
cellular tumour A tumour composed mainly of closely packed cells.
(05 Mar 2000)
coordinate regulation The expression of many different genes at once.
(09 Oct 1997)
self-regulation A three-stage strategy patients are taught to use in order to end risky health-associated behaviours such as smoking and overeating. 1. Self-monitoring (self-observation), the first stage in self-regulation involves the individual's deliberately attending to and recording his or her own behaviour; 2. Self-evaluation, the second stage, in which the individual assesses what was learned by self-monitoring, such as how often and where one smokes, and uses those observational data to establish health goals or criteria; 3. Self-reinforcement, the third stage, in which the individual rewards him/herself for each behavioural success on the road to that goal, thereby enhancing the chance of reaching it.
(05 Mar 2000)
negative regulation Negative feedback in biological systems mediated by allosteric regulatory enzymes.
(18 Nov 1997)
down-regulation <physiology> Development of a refractory or tolerant state consequent upon repeated administration of a pharmacologically or physiologically active substance.
It is the process that decreases ligand and receptor interactions or reduces the responsiveness of a cell to a stimulus following first exposure.
This is often accompanied by an initial decrease in affinity of receptors for the agent and a subsequent reduction in the number of available receptors expressed on the surface which can result from internalisation of the ligand:receptor complex or from decreased expression of the receptor.
Classically the concept referred to hormone receptors but contemporary usage includes other cell surface receptors.
(03 Jul 1999)
immunity, cellular Those manifestations of the immune response which are mediated by antigen-sensitised T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
(12 Dec 1998)
target regulation <physiology> General term for an interaction between neurons and their targets by which target derived signals influence the differentiation of the innervating neurons.
(18 Nov 1997)
enzyme regulation <biochemistry> Control of the rate of a reaction catalyzed by an enzyme by some effector (e.g., inhibitors or activators) or by alteration of some condition (e.g., pH or ionic strength).
(05 Mar 2000)
facility regulation and control Formal voluntary or governmental procedures and standards required of hospitals and health or other facilities to improve operating efficiency, and for the protection of the consumer.
(12 Dec 1998)
feedback regulation <physiology> Control mechanism that uses the consequences of a process to regulate the rate at which the process occurs: if, for example: the products of a reaction inhibit the reaction from proceeding (or slow down the rate of the reaction), then there is negative feedback, something that is very common in metabolic pathways.
Positive feedback is liable to lead to exponential increase and may be explosively dangerous in some cases.
Other examples are the action of voltage dependent sodium channels in generating action potentials and the activation of blood clotting factors V and VIII by thrombin. Without damping, feedback can lead to resonance (hunting) and oscillation in the system.
(18 Nov 1997)
up-regulation Opposite of down-regulation.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • eddy current
    (Àü)¿Í»ó Àü·ù(ÀÚÀåÀ» º¯µ¿½Ãų ¶§,µµÃ¼ ¾È¿¡ »ý±è)
  • electric current
    Àü·ù
  • galvanic current
    Á÷·ù
  • grid current
    ±×¸®µå Àü·ù !
  • main current
    ÁÖ·ù
  • neutral current
    Á߸³Àû ¼Ò¸³ÀÚ·ù;Áß¼º Ä¿·»Æ®
  • petty current deposit
    ¼Ò¾×´çÁ¿¹±Ý
  • price current
    ´çÀÏ °¡°Ý;»ç°¡Ç¥;½Ã¼¼Ç¥
  • rip current
    Á¶Ãæ;À̾ȷù;½ÉÀû °¥µî
  • tidal current
    Á¶·ù
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á